Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis

Clinical Therapeutics

Volumn 39, Issue 7, 2017, Pages 1479-1506.e45

  Shamliyan, Tatyana A ^a   Dospinescu, Paula ^b  

^a ELSEVIER MASSON   (France)

^b NHS GRAMPIAN   (United Kingdom)

Author keywords

abatacept; belimumab; blisibimod; rigerimod; rituximab; systemic lupus erythematosus

Indexed keywords

ABATACEPT; ANIFROLUMAB; ATACICEPT; AZATHIOPRINE; BELIMUMAB; BIOLOGICAL RESPONSE MODIFIER; BLISIBIMOD; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EPRATUZUMAB; FORIGERIMOD; HYDROXYCHLOROQUINE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PLACEBO; PREDNISONE; RITUXIMAB; SIFALIMUMAB; TABALUMAB; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT;

ADJUVANT THERAPY; ADULT; ADVERSE EVENT; ATTRIBUTABLE RISK; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; DISEASE SEVERITY; DRUG EFFECT; EMBASE; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85021439883     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2017.05.359     Document Type: Review

References (85)

1. Feldman, C.H., Hiraki, L.T., Liu, J., et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 65 (2013), 753–763.
2. Oglesby, A., Korves, C., Laliberte, F., et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy 12 (2014), 179–190.
3. Kamal, A., Khamashta, M., The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev 13 (2014), 1094–1101.
4. Croca, S.C., Rodrigues, T., Isenberg, D.A., Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 50 (2011), 1424–1430.
5. Rees, F., Doherty, M., Grainge, M.J., et al. Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012. Rheumatology (Oxford) 55 (2016), 854–860.
6. Gordon, C., Amissah-Arthur, M.B., Gayed, M., et al. The BSR and BHPR guideline for the management of systemic lupus erythematosus in adults. Rheumatology, 2016 http://www.rheumatology.org.uk/includes/documents/cm_docs/2016/f/full_guideline_for_the_management_of_systemic_lupus_erythematosus_in_adults.pdf Accessed in July 17, 2016.
7. Institute of Medicine. Graham, R.M.M., Wolman, D.M., Greenfield, S., Steinberg, E., (eds.) Clinical practice guidelines we can trust, 2011, National Academies Press, Washington (DC) http://nationalacademies.org/hmd/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx.
8. Tunnicliffe, D.J., Singh-Grewal, D., Kim, S., et al. Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res (Hoboken) 67 (2015), 1440–1452.
9. Higgins, J., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions. Version 5.1.0, 2011, The Cochrane Collaboration, London Cochrane book series.
10. Slutsky, J., Atkins, D., Chang, S., Sharp, B.A., AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol 63 (2010), 481–483.
11. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 42 (1999), 1785–1796.
12. Hahn, B.H., McMahon, M.A., Wilkinson, A., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64 (2012), 797–808.
13. Balshem, H.S.A., Ansari, M., Norris, S., et al. Finding Grey Literature Evidence and Assessing for Outcome and Analysis Reporting Biases When Comparing Medical Interventions: AHRQ and the Effective Health Care Program. AHRQ and the Effective Health Care Program Methods Guide for Comparative Effectiveness Reviews. ii. 2013; Prepared by the Oregon Health and Science University and the University of Ottawa Evidence-based Practice Centers under Contract Nos. 290-2007-10057-I and 290-2007-10059-I. (AHRQ Publication No. 13(14)-EHC096-EF.), 2013, Agency for Healthcare Research and Quality, Rockville, MD www.effectivehealthcare.ahrq.gov/reports/final.cfm.
14. Shamliyan TA, K.R., Ansari, M.T., et al. Development of Quality Criteria To Evaluate Nontherapeutic Studies of Incidence, Prevalence, or Risk Factors of Chronic Diseases: Pilot Study of New Checklists [Internet]. 2011, Agency for Healthcare Research and Quality (US)., Rockville (MD) https://www.ncbi.nlm.nih.gov/books/NBK53272/.
15. Fu, R., Gartlehner, G., Grant, M., et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol 64 (2011), 1187–1197.
16. Robinson KA, W.E., O'Neil, M.E., Anderson, J.K., et al. Integration of Existing Systematic Reviews. AHRQ Publication No. 14-EHC016-EF Research White Paper (Prepared by the Scientific Resource Center under Contract No 290-2012-00004-C), 2014, Agency for Healthcare Research and Quality), AHRQ Publication No. 14-EHC016-EF (Rockville, MD www.effectivehealthcare.ahrq.gov/reports/final.cfm.
17. Levine, M., Ensom, M.H., Post hoc power analysis: an idea whose time has passed?. Pharmacotherapy 21 (2001), 405–409.
18. Goodman, S.N., Berlin, J.A., The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 121 (1994), 200–206.
19. Yuan, K.H., Maxwell, S., On the post hoc power in testing mean differences. Journal of Educational and Behavioral Statistics 30 (2005), 141–167.
20. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No 10(14)-EHC063-EF. 2014; Rockville, MD (Chapters available at: www.effectivehealthcare.ahrq.gov): https://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318.
21. Guyatt, G.H., Oxman, A.D., Kunz, R., et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 64 (2011), 1283–1293.
22. Shea, B.J., Hamel, C., Wells, G.A., et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62 (2009), 1013–1020.
23. Viswanathan, M., Berkman, N.D., Dryden, D.M., Hartling, L., assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI Item Bank. AHRQ Methods for Effective Health Care, 2013 Contract No. 290-2007-10056-I.
24. Higgins, J.P., Altman, D.G., Gotzsche, P.C., et al. The Cochrane Collaboration׳s tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
25. Guyatt, G.H., Oxman, A.D., Sultan, S., et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 64 (2011), 1311–1316.
26. Grading of Recommendations Assessment DaEGWG. GRADE Handbook. http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html#h.fueh5iz0cor4.
27. Bramer, W.M., Giustini, D., Kramer, B.M., Comparing the coverage, recall, and precision of searches for 120 systematic reviews in Embase, MEDLINE, and Google Scholar: a prospective study. Systematic reviews, 5, 2016, 39.
28. Bruce, I.N., Urowitz, M., Van Vollenhoven, R., et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus 25 (2015), 699–709.
29. Manzi, S., Sanchez-Guerrero, J., Merrill, J.T., et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71 (2012), 1833–1838.
30. Rovin, B.H., Dooley, M.A., Radhakrishnan, J., et al. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials. Lupus 25 (2016), 1597–1601.
31. Strand, V., Levy, R.A., Cervera, R., et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 73 (2014), 838–844.
32. van Vollenhoven, R.F., Petri, M.A., Cervera, R., et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71 (2012), 1343–1349.
33. Wallace, D.J., Navarra, S., Petri, M.A., et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 22 (2013), 144–154.
34. Dooley, M.A., Houssiau, F., Aranow, C., et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22 (2013), 63–72.
35. Henderson, L.K., Masson, P., Craig, J.C., et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 61 (2013), 74–87.
36. Feldman, C.H., Hiraki, L.T., Winkelmayer, W.C., et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis and Rheumatology 67 (2015), 1577–1585.
37. Ginzler, E.M., Wallace, D.J., Merrill, J.T., et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 41 (2014), 300–309.
38. Human Genome Sciences Inc, a G. S. K. Company GlaxoSmithKline. A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02, 2016 http://ClinicalTrials.gov/show/NCT00583362.
39. Merrill, J.T., Ginzler, E.M., Wallace, D.J., et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 64 (2012), 3364–3373.
40. Strand, V., Petri, M., Kalunian, K., et al. Epratuzumab for patients with moderate to severe flaring SLE: Health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (United Kingdom) 53 (2014), 502–511.
41. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 66 (2014), 3096–3104.
42. Andrade-Ortega, L., Irazoque-Palazuelos, F., Lopez-Villanueva, R., et al. Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study. Reumatologia Clinica 6 (2010), 250–255.
43. Furie, R., Nicholls, K., Cheng, T.T., et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66 (2014), 379–389.
44. Furie, R., Petri, M., Zamani, O., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63 (2011), 3918–3930.
45. Furie R, M.J., Werth, V., Khamashta, M., et al. Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol, 67(suppl 10), 2015 http://acrabstracts.org/abstract/anifrolumab-an-anti-interferon-alpha-receptor-monoclonal-antibody-in-moderate-to-severe-systemic-lupus-erythematosus-sle/ Accessed August 3, 2016.
46. Furie, R.A., Leon, G., Thomas, M., et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Arthritis Rheumato 69:1 (2017 Jan), 122–130, 10.1002/art.39809 Epub 2016 Dec 2. PMID: 27390168.
47. Gordon, C., Wofsy, D., Wax, S., et al. Post-hoc analysis of the Phase II/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol 69:1 (2017 Jan), 122–130, 10.1002/art.39809 Epub 2016 Dec 2. PMID: 27390168.
48. Human Genome Sciences I. Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE), 2005 http://ClinicalTrials.gov/show/NCT00071487.
49. Human Genome Sciences I, GlaxoSmithKline. A Study of Belimumab in Subjects With Systemic Lupus Erythematosus, 2009 http://ClinicalTrials.gov/show/NCT00410384.
50. Human Genome Sciences I, GlaxoSmithKline. A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE), 2009 http://ClinicalTrials.gov/show/NCT00424476.
51. Isenberg, D., Gordon, C., Licu, D., et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 74:11 (2015 Nov), 2006–2015, 10.1136/annrheumdis-2013-205067 Epub 2014 Jun 20. PMID: 24951103 PMCID: PMC4680140.
52. Isenberg, D.A., Petri, M., Kalunian, K., et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75 (2016), 323–331.
53. Kalunian, K.C., Merrill, J.T., Maciuca, R., et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 75:1 (2016 Jan), 196–202, 10.1136/annrheumdis-2014-206090 Epub 2015 Jun 2 PMID: 26038091.
54. Khamashta, M., Merrill, J.T., Werth, V.P., et al. Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75:11 (2016 Nov), 1909–1916, 10.1136/annrheumdis-2015-208562 Epub 2016 Mar 23. PMID: 27009916 PMCID: PMC5099191.
55. Merrill, J., Buyon, J., Furie, R., et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 20 (2011), 709–716.
56. Merrill, J.T., Burgos-Vargas, R., Westhovens, R., et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62 (2010), 3077–3087.
57. Merrill, J.T., Neuwelt, C.M., Wallace, D.J., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62 (2010), 222–233.
58. Merrill, J.T., Van Vollenhoven, R.F., Buyon, J.P., et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75 (2016), 332–340.
59. Mysler, E.F., Spindler, A.J., Guzman, R., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65 (2013), 2368–2379.
60. National Institute of A, Infectious D. Etanercept for the Treatment of Lupus Nephritis, 2009 National Institute of Allergy and Infectious Diseases (NIAID) http://ClinicalTrials.gov/show/NCT00447265.
61. Navarra, S.V., Guzman, R.M., Gallacher, A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377 (2011), 721–731.
62. Rovin, B.H., Furie, R., Latinis, K., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64 (2012), 1215–1226.
63. Wallace, D.J., Gordon, C., Strand, V., et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (United Kingdom) 52 (2013), 1313–1322.
64. Wallace, D.J., Hobbs, K., Clowse, M.E., et al. Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study. Arthritis Care and Research 68 (2016), 534–543.
65. Wallace, D.J., Kalunian, K., Petri, M.A., et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73 (2014), 183–190.
66. Wallace, D.J., Stohl, W., Furie, R.A., et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61 (2009), 1168–1178.
67. Zimmer, R., Scherbarth, H.R., Rillo, O.L., et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 72 (2013), 1830–1835.
68. Askanase, A.D., Yazdany, J., Molta, C.T., Post-marketing experiences with belimumab in the treatment of SLE patients. Rheum Dis Clin North Am 40:3 (2014), 507–517 viii.
69. MedImmune LLC. A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus. 2012, https://ClinicalTrials.gov/show/NCT01438489.
70. Thanou, A., Merrill, J.T., Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nat Rev Rheumatol 10 (2014), 23–34.
71. Leone, A., Sciascia, S., Kamal, A., Khamashta, M., Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies. Expert Rev Clin Immunol 11 (2015), 109–116.
72. Hoi, A., Littlejohn, G., Is there still a role for abatacept in the treatment of lupus?. Expert Opin Biol Ther 14 (2014), 1345–1350.
73. Mok, C.C., Abatacept for systemic lupus erythematosus: the outlook. Expert Opin Biol Ther 12 (2012), 1559–1561.
74. Richez, C., Truchetet, M.E., Schaeverbeke, T., Bannwarth, B., Atacicept as an investigated therapy for rheumatoid arthritis. Expert Opin Investig Drugs 23 (2014), 1285–1294.
75. Anthera Pharmaceuticals. PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus. 2010 https://ClinicalTrials.gov/show/NCT01162681.
76. UCB Pharma, Study of Epratuzumab in Systemic Lupus Erythematosus (SLE). https://ClinicalTrialsgov/show/NCT00383214. 2007.
77. UCB Pharma, Study of Epratuzumab in Systemic Lupus Erythematosus. https://ClinicalTrialsgov/show/NCT00111306. 2007.
78. Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE). 2015, https://ClinicalTrials.gov/show/NCT01261793.
79. Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus. 2016, https://ClinicalTrials.gov/show/NCT01408576.
80. Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus. 2015, https://ClinicalTrials.gov/show/NCT01262365.
81. Singh, J.A., Hossain, A., Kotb, A., Wells, G., Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med, 14, 2016, 137.
82. Singh, J.A., Hossain, A., Kotb, A., et al. Treatments for lupus nephritis: a systematic review and network metaanalysis. J Rheumatol 43 (2016), 1801–1815.
83. Singh, J.A., Hossain, A., Kotb, A., Wells, G.A., Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Systematic reviews, 5, 2016, 155.
84. Henderson, L., Masson, P., Craig, J.C., et al. Treatment for lupus nephritis. Cochrane Database Syst Rev, 12, 2012 CD002922.
85. Palmer, S.C., Tunnicliffe, D.J., Singh-Grewal, D., et al. induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis, 2017 Feb 20 pii: S0272-6386(17)30036-7. http://dx.doi.org/10.1053/j.ajkd.2016.12.008. [Epub ahead of print] PMID: 28233655.